Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN1 | Q05586 | 3/20 | 0.63 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.63 |
| ▸ | GRIN2D | O15399 | 2/20 | 0.63 |
| ▸ | GRIN3B | O60391 | 2/20 | 0.63 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.63 |
| ▸ | GRIN2C | Q14957 | 2/20 | 0.63 |
| ▸ | GRIN3A | Q8TCU5 | 2/20 | 0.63 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.51 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29088828 | 1.00 | GRIN1 (0.63) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL31757256 | 0.91 | GRIN1 (0.64) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL25889589 | 0.89 | GRIN1 (0.58) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL29515670 | 0.86 | GRIN1 (0.64) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL21488779 | 0.86 | GRIN1 (0.64) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL21487993 | 0.86 | GRIN1 (0.64) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL28474229 | 0.86 | GRIN1 (0.64) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL31757289 | 0.85 | GRIN1 (0.54) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL28470733 | 0.85 | GRIN1 (0.53) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B | |
| SCHEMBL31757296 | 0.84 | GRIN1 (0.53) | GRIN1GRIN2AGRIN2DGRIN3BGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4681777-A2 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2026-01-21 | — | — | EP | claimed |
| US-20220411365-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2022-12-29 | — | — | US | claimed |
| EP-4681777-A2 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPharma Ltd. (KY) | 2026-01-21 | — | — | EP | disclosed |
| EP-3737665-B1 | PRODRUGS OF KETAMINE, COMPOSITIONS AND USES THEREOF | XWPHARMA LTD (KY) | 2026-01-07 | — | — | EP | disclosed |
| US-20250352496-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPHARMA LTD (KY) | 2025-11-20 | — | — | US | disclosed |
| US-12396966-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | XWPharma Ltd. (KY) | 2025-08-26 | — | — | US | disclosed |
| EP-4559522-A2 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2025-05-28 | — | — | EP | disclosed |
| EP-4384145-B1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPHARMA LTD (KY) | 2025-04-23 | — | — | EP | disclosed |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2025-04-17 | — | — | US | disclosed |
| US-12209060-B2 | Ketamine derivatives and compositions thereof | XWPharma Ltd. (KY) | 2025-01-28 | — | — | US | disclosed |
| EP-4384145-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2024-06-19 | — | — | EP | disclosed |
| CN-114805139-B | Prodrugs of ketamine, compositions and uses thereof | 凯瑞康宁生物工程（武汉）有限公司 | 2023-10-20 | — | — | CN | disclosed |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-09-14 | — | — | US | disclosed |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | XWPharma Ltd. (KY) | 2023-07-04 | — | — | US | disclosed |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-03-30 | — | — | US | disclosed |
| WO-2023018966-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | XWPharma Ltd. (KY) | 2023-02-16 | — | — | WO | disclosed |
| US-20220411365-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | XWPharma Ltd. (KY) | 2022-12-29 | — | — | US | disclosed |
| US-11440874-B2 | Ketamine derivatives and compositions thereof | XWPharma Ltd. (KY) | 2022-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12209060-B2 | Ketamine derivatives and compositions thereof | OPRK1, KCNK10, KCNK17 | GRIN1 74/4885GRIN2A 54/4885GRIN2D 93/4885 |
| US-11440874-B2 | Ketamine derivatives and compositions thereof | OPRK1, KCNK10, KCNK17 | GRIN1 74/4885GRIN2A 54/4885GRIN2D 93/4885 |
| US-11690811-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | OPRK1, KCNK5, KCNK17 | GRIN1 51/4885GRIN2A 35/4885GRIN2D 27/4885 |
| US-12396966-B2 | Pharmaceutical compositions and oral dosage forms of ketamine derivatives | OPRK1, KCNK5, KCNK17 | GRIN1 51/4885GRIN2A 35/4885GRIN2D 27/4885 |
| US-20250352496-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | GRIN1 51/4885GRIN2A 35/4885GRIN2D 27/4885 |
| US-20250122149-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | GRIN1 74/4885GRIN2A 54/4885GRIN2D 93/4885 |
| US-20230098084-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | GRIN1 51/4885GRIN2A 35/4885GRIN2D 27/4885 |
| US-20220411365-A1 | KETAMINE DERIVATIVES AND COMPOSITIONS THEREOF | OPRK1, KCNK10, KCNK17 | GRIN1 74/4885GRIN2A 54/4885GRIN2D 93/4885 |
| US-20230285325-A1 | PHARMACEUTICAL COMPOSITIONS AND ORAL DOSAGE FORMS OF KETAMINE DERIVATIVES | OPRK1, KCNK5, KCNK17 | GRIN1 51/4885GRIN2A 35/4885GRIN2D 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.